Europe Parenteral Nutrition Market Forecast to 2030 - Regional Analysis

List of Tables

The Europe parenteral nutrition market was valued at US$ 2,404.63 million in 2022 and is expected to reach US$ 3,958.07 million by 2030; it is estimated to record a CAGR of 6.4% from 2022 to 2030.

Surge in Cases of Malnutrition and Premature Births Drive Europe Parenteral Nutrition Market

Malnutrition includes being undernourished, overweight or obese, having inadequate vitamins or minerals, and having a non-communicable disease due to a bad diet. As per World Health Organization (WHO) data, ~1.9 billion adults were overweight or obese, whereas 462 million were underweight in 2021. Additionally, 39 million children under the age of 5 were overweight, 149 million had stunted growth and development as a result of a chronic lack of nutrient-rich food in their diets, and 45 million were wasted (too thin for height). Furthermore, ~45% of deaths among children aged less than 5 are associated with undernutrition. As per the July 2022 data of the United Nations International Children's Emergency Fund (UNICEF), the prevalence of undernourishment reached 9.3% in 2020 from 8.0% in 2019; it further jumped to 9.8% in 2021.

According to a Specialized Nutrition Europe study, ~40% of hospitalized adult patients were malnourished in Europe in 2019. As per a study titled "A multi-centre survey on hospital malnutrition," published in 2021, approximately 11-45% of patients in hospitals and home care settings in England suffered from malnutrition. Nutritional support delivered through parenteral methods, depending on the need, is an important and appropriate way of treating most malnutrition cases.

Preterm birth refers to a baby being born at a significantly early stage, i.e., before the completion of 37 weeks of pregnancy. As per the WHO data published in 2023, ~13.4 million preterm births (more than 1 in 10 births) were reported worldwide in 2020. On average, 12% of babies in low-income countries are born too early, compared to 9% in high-income countries. A large number of premature babies suffer from low weight and undeveloped immunity, which puts their lives at risk. Parenteral nutrition is preferred in preterm infants due to sucking or swallowing difficulties as a complication of an immature birth or due to neuromuscular, heart, or other disorders. When estimated energy and nutritional requirements cannot be safely met by enteral route right after birth, parenteral nutrition (PN) is part of the routine nutrition care for premature neonates and infants.

Thus, the huge burden of malnutrition in children and adults and the high number of preterm births drive the demand for parenteral nutrition formulae and products, which drives the market.

Europe Parenteral Nutrition Market Overview

In Germany, there are several cases related to overweight issues, obesity, and malnutrition. According to the Robert Koch Institute, approximately two-thirds of men and over half of women were overweight in 2022. Nutritional deficiencies lead to unfavorable outcomes and lower quality of life in patients with malignancies. Patients with active tumors often lack sufficient food; hence, parenteral and enteral nutrition is used to prevent or reduce progressive weight loss. According to the Association of the Scientific Medical Societies in Germany, patients with severe gastrointestinal defects, such as radiation enteritis, can benefit from parenteral nutrition. In most cases, artificial nutrition stabilizes or increases body weight and body fat mass.

Moreover, the incidence of H. pylori infection in Germany is high, which is a significant cause of gastric cancer. According to a study (2020) in the Clinical Microbiology and Infection Journal (ELSEVIER), Helicobacter pylori infected ~25% of the total population in Germany and caused gastritis that becomes more complicated with gastric adenocarcinoma. Furthermore, Germany has a significant incidence rate of stomach cancer, which promotes diagnostic procedures in the country. According to the latest data from the International Agency for Research on Cancer, the estimated age-standardized incidence rate for stomach cancer in Germany is 7 per 100,000, and the crude rate is 18.29. The abovementioned factors are driving the parenteral nutrition market in Germany.

Europe Parenteral Nutrition Market Revenue and Forecast to 2030 (US$ Million)

Europe Parenteral Nutrition Market Segmentation

The Europe parenteral nutrition market is segmented based on nutrient type, end user, and country. Based on nutrient type, the Europe parenteral nutrition market is categorized into single dose amino acid solution, parenteral lipid emulsion, carbohydrates, trace elements, and vitamins and minerals. The single dose amino acid solution segment held the largest market share in 2022.

By end user, the Europe parenteral nutrition market is segmented into hospitals, clinics, and others. The hospitals segment held the largest market share in 2022.

Based on country, the Europe parenteral nutrition market is segmented into s. Germany dominated the Europe parenteral nutrition market share in 2022.

ICU Medical Inc, Grifols SA, Pfizer Inc, Otsuka Pharmaceuticals Co Ltd, Baxter International Inc, B Braun SE, Fresenius Kabi AG, Aculife Healthcare Pvt Ltd, and Vifor Pharma Management AG are some of the leading players operating in the Europe parenteral nutrition market.

Product Code: BMIRE00030424

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Parenteral Nutrition Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Rise in Prevalence of Gastrointestinal Diseases
- 4.1.2 Surge in Cases of Malnutrition and Premature Births
4.2 Market Restraints
- 4.2.1 Mechanical, Gastrointestinal, and Metabolic Complications Associated with Parenteral Feeding Systems
4.3 Market Opportunities
- 4.3.1 New Product Developments by Companies
4.4 Future Trends
- 4.4.1 Innovation in Formulations of Nutrition Products
4.5 Impact Analysis

5. Parenteral Nutrition Market - Europe Market Analysis

5.1 Overview
5.2 Parenteral Nutrition Market Revenue (US$ Mn), 2020 - 2030

6. Europe Parenteral Nutrition Market Analysis - by Nutrient Type

6.1 Overview
6.2 Single Dose Amino Acid Solution
- 6.2.1 Overview
- 6.2.2 Single Dose Amino Acid Solution: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Parenteral Lipid Emulsion
- 6.3.1 Overview
- 6.3.2 Parenteral Lipid Emulsion: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Carbohydrates
- 6.4.1 Overview
- 6.4.2 Carbohydrates: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Trace Elements
- 6.5.1 Overview
- 6.5.2 Trace Elements: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Vitamins and Minerals
- 6.6.1 Overview
- 6.6.2 Vitamins and Minerals: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Parenteral Nutrition Market Analysis - by End User

7.1 Overview
7.2 Hospitals
- 7.2.1 Overview
- 7.2.2 Hospitals: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Clinics
- 7.3.1 Overview
- 7.3.2 Clinics: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Parenteral Nutrition Market - Country Analysis

8.1 Europe
- 8.1.1 Europe: Parenteral Nutrition Market - Revenue and Forecast Analysis - by Country
  - 8.1.1.1 Germany: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.1.1 Overview
    - 8.1.1.1.2 Germany: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.1.3 Germany: Parenteral Nutrition Market Breakdown, by Nutrient Type
    - 8.1.1.1.4 Germany: Parenteral Nutrition Market Breakdown, by End User
  - 8.1.1.2 United Kingdom: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.2.1 Overview
    - 8.1.1.2.2 United Kingdom: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.2.3 United Kingdom: Parenteral Nutrition Market Breakdown, by Nutrient Type
    - 8.1.1.2.4 United Kingdom: Parenteral Nutrition Market Breakdown, by End User
  - 8.1.1.3 France: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.3.1 Overview
    - 8.1.1.3.2 France: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.3.3 France: Parenteral Nutrition Market Breakdown, by Nutrient Type
    - 8.1.1.3.4 France: Parenteral Nutrition Market Breakdown, by End User
  - 8.1.1.4 Italy: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.4.1 Overview
    - 8.1.1.4.2 Italy: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.4.3 Italy: Parenteral Nutrition Market Breakdown, by Nutrient Type
    - 8.1.1.4.4 Italy: Parenteral Nutrition Market Breakdown, by End User
  - 8.1.1.5 Spain: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.5.1 Overview
    - 8.1.1.5.2 Spain: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.5.3 Spain: Parenteral Nutrition Market Breakdown, by Nutrient Type
    - 8.1.1.5.4 Spain: Parenteral Nutrition Market Breakdown, by End User
  - 8.1.1.6 Rest of Europe: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.6.1 Overview
    - 8.1.1.6.2 Rest of Europe: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
    - 8.1.1.6.3 Rest of Europe: Parenteral Nutrition Market Breakdown, by Nutrient Type
    - 8.1.1.6.4 Rest of Europe: Parenteral Nutrition Market Breakdown, by End User

9. Industry Landscape

9.1 Overview
- 9.1.1 Overview

10. Company Profiles

10.1 ICU Medical Inc
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 Grifols SA
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 Pfizer Inc
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Otsuka Pharmaceuticals Co Ltd
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 Baxter International Inc
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
10.6 B Braun SE
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments
10.7 Fresenius Kabi AG
- 10.7.1 Key Facts
- 10.7.2 Business Description
- 10.7.3 Products and Services
- 10.7.4 Financial Overview
- 10.7.5 SWOT Analysis
- 10.7.6 Key Developments
10.8 Vifor Pharma Management AG
- 10.8.1 Key Facts
- 10.8.2 Business Description
- 10.8.3 Products and Services
- 10.8.4 Financial Overview
- 10.8.5 SWOT Analysis
- 10.8.6 Key Developments
10.9 Aculife Healthcare Pvt Ltd
- 10.9.1 Key Facts
- 10.9.2 Business Description
- 10.9.3 Products and Services
- 10.9.4 Financial Overview
- 10.9.5 SWOT Analysis
- 10.9.6 Key Developments

11. Appendix

11.1 About The Insight Partners
11.2 Glossary of Terms